spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  triptorelin 

 HSMN NewsFeed - 30 Jun 2017
Arbor Pharmaceuticals, LLC and Debiopharm International SA Announce U.S. FDA Approval for Triptodur(TM), Triptorelin 6-month Formulation, in the Treatment of Central Precocious Puberty (CPP)
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 May 2015
Debiopharm International SA Announces Phase III Positive Results for Triptorelin 6-month Formulation in the Management of Central Precocious Puberty (CPP)
Biopharmaceuticals
 HSMN NewsFeed - 27 May 2014
Orient EuroPharma and Debiopharm Group(TM) Announce Their Partnership and the Launch of Pamorelin(R) LA in Singapore
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Feb 2014
Ipsen announces positive top line results from phase III clinical study of Decapeptyl(R) (triptorelin pamoate) 11.25 mg administered subcutaneously in patients with prostate cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Dec 2012
Dr. Reddy's Launches Debiopharm's Pamorelin(R) LA in India for the Treatment of Locally Advanced or Metastatic, Hormone-Dependent Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Jul 2012
Debiopharm Group(TM) - First Patient Treated in Phase III Study With Subcutaneous Administration of Debio 8206 for Treatment of Advanced Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Feb 2010
Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Nov 2009
Ipsen's Decapeptyl(R) 6-Month Formulation Receives Marketing Authorization in France for the Treatment of Locally Advanced or Metastatic Prostate Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 21 Jul 2009
Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 14 Jul 2009
Watson Pharmaceuticals Receives a Complete Response Letter for Its 24-Week Formulation of TRELSTAR(R) (triptorelin pamoate) NDA from US FDA
Biopharmaceuticals Urology Oncology FDA
 HSMN NewsFeed - 23 Jun 2009
Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries
Biopharmaceuticals
 HSMN NewsFeed - 21 May 2009
Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB)
Biopharmaceuticals Urology
 HSMN NewsFeed - 11 May 2009
Debiopharm and Mepha Sign Distribution Agreement for Pamorelin(R) LA
Biopharmaceuticals Oncology Distribution
 HSMN NewsFeed - 7 Apr 2009
Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
Biopharmaceuticals Urology
 HSMN NewsFeed - 8 Oct 2008
Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH)
Biopharmaceuticals FDA Urology
 HSMN NewsFeed - 21 May 2008
Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
Biopharmaceuticals Urology
 HSMN NewsFeed - 15 May 2008
Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
Biopharmaceuticals Licensing
 HSMN NewsFeed - 30 Apr 2008
FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceutical's TRELSTAR(R) DEPOT and TRELSTAR(R) LA
Biopharmaceuticals Devices Drug Delivery Oncology FDA
 HSMN NewsFeed - 3 Mar 2008
GTx Announces Additional Top Line Phase III Data Demonstrating Toremifene Citrate 80 mg Reduced Hot Flashes in Men with Prostate Cancer on Androgen Deprivation Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Feb 2008
GTx's Toremifene Citrate 80 mg Meets Primary and Key Endpoints in Phase III Trial in Advanced Prostate Cancer Patients on Androgen Deprivation Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Feb 2008
Ipsen: Clinical Update For Decapeptyl(R) 6-Month Formulation in Advanced Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Feb 2008
Clinical Update - Decapeptyl(R)/Trelstar(R) 6-Month Formulation in Advanced Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Jan 2008
Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
Biopharmaceuticals Urology
 HSMN NewsFeed - 3 Nov 2006
GenSci Expects Topical Molgramostim Gel Approval in 2007
Biopharmaceuticals Wound Care Regulatory
Return to NewsFeed  

 Additional items found! 11

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 11 additional stories matching:
triptorelin
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.